Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: Virus fate and activation of B- and T-cell immune responses in comparison with the western reserve strain and advantages as a vaccine

Journal of Virology

Volumn 74, Issue 2, 2000, Pages 923-933

  Ramírez, Juan C ^a   Gherardi, M Magdalena ^a   Esteban, Mariano ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 6; LUCIFERASE; TUMOR NECROSIS FACTOR ALPHA; VACCINIA VACCINE; VIRUS ANTIGEN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMORAL IMMUNITY; IMMUNIZATION; INOCULATION; MOUSE; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REPORTER GENE; VACCINIA VIRUS; VIRUS ATTENUATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

3T3 CELLS; ANIMALS; ANTIGENS, VIRAL; B-LYMPHOCYTES; BETA-GALACTOSIDASE; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELL LINE; CERCOPITHECUS AETHIOPS; CRICETINAE; CYTOKINES; GENE EXPRESSION; GENES, VIRAL; GENETIC VECTORS; HELA CELLS; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; RECOMBINATION, GENETIC; T-LYMPHOCYTES; VACCINIA VIRUS; VIRAL VACCINES;

EID: 0342470981     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.2.923-933.2000     Document Type: Article

References (59)

1. Altenburger, W., C.-P. Süter, and J. Altenburger. 1989. Partial deletion of the human host range in the attenuated vaccinia virus MVA. Arch. Virol. 105:15-27.
2. Antoine, G., F. Scheiflinger, F. Dorner, and F. G. Falkner. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other Orthopoxviruses. Virology 244:365-396.
3. Bachmann, M. F., B. Odermatt, H. Hengartner, and R. M. Zinkernagel. 1996. Induction of long-lived germinal centers associated with persisting antigen after viral infection. J. Exp. Med. 183:2259-2269.
4. Bachmann, M. F., T. M. Kündig, H. Hengartner, and R. M. Zinkernagel. 1997. Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells: T cell memory without "memory T cells"? Proc. Natl. Acad. Sci. USA 94:640-645.
5. Belyakov, I. M., L. S. Wyatt, J. D. Ahlers, P. Earl, C. D. Pendleton, B. L. Kelsall, W. Strober, B. Moss, and J. A. Berzofsky. 1998. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J. Virol. 72:8264-8272.
6. Belyakov, I. M., B. Moss, W. Strober, and J. A. Berzofsky. 1999. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl. Acad. Sci. USA 96: 4512-4517.
7. Bender, B. S., C. A. Rowe, S. F. Taylor, L. S. Wyatt, B. Moss, and P. A. Small, Jr. 1996. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J. Virol. 70:6418-6424.
8. Blanchard, T. J., A. Alcamí, P. Andrea, and G. L. Smith. 1998. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol. 79:1159-1167.
9. Bluestone, J. A. 1995. New perspectives of CD28-B7-mediated T cell co-stimulation. Immunity 2:555-559.
10. Buller, R. M., and G. J. Palumbo. 1991. Poxvirus pathogenesis. Microbiol. Rev. 55:80-122.
11. Carroll, M. W., W. Overwijk, R. S. Chamberlain, S. A. Rosenberg, B. Moss, and N. P. Restifo. 1997. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15:387-394.
12. Cooney, E. L., A. C. Collier, P. D. Greenberg, R. W. Coombs, J. Zarling, D. E. Arditti, M. C. Hoffman, S. L. Hu, and L. Corey. 1991. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337:567-572.
13. Cousens, L. P., J. S. Orange, H. C. Sue, and C. A. Biron. 1997. Interferon-α/β inhibition of interleukin 12 and interferon-γ production in vitro and endo-genously during viral infection. Proc. Natl. Acad. Sci. USA 94:634-639.
14. Cox, W. I., J. Tartaglia, and E. Paoletti. 1992. Poxvirus recombinants as live vaccines, p. 123-162. In M. M. Binns and G. L. Smith (ed.), Recombinant poxviruses. CRC Press, Boca Raton, Fla.
15. Dallo, S., and M. Esteban. 1987. Isolation and characterization of attenuated mutants of vaccinia virus. Virology 159:408-422.
16. Dallo, S., J.-S. Maa, J. R. Rodriguez, D. Rodriguez, and M. Esteban. 1989. Humoral immune response elicited by highly attenuated variants of vaccinia virus and by an attenuated recombinant expressing HIV-1 envelope protein. Virology 173:323-329.
17. Drexler, I., K. Heller, B. Wahren, V. Erfle, and G. Sutter. 1998. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79:347-352.
18. Durbin, A. P., L. S. Wyatt, J. Siew, B. Moss, and B. R. Murphy. 1998. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys. Vaccine 16:1324-1330.
19. Fenner, F. 1989. Risks and benefits of vaccinia vaccine use in the worldwide smallpox eradication campaign. Res. Virol. 140:465-466.
20. Gherardi, M. M., J. C. Ramirez, D. Rodriguez, J. R. Rodriguez, G. Sano, F. Zavala, and M. Esteban. 1999. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 env in a dose-dependent manner. J. lmmunol. 162:6724-6733.
21. Hanke, T., T. J. Blanchard, J. Schneider, C. M. Hannan, M. Becker, S. C. Gilbert, A. V. S. Hill, G. L. Smith, and A. McMichael. 1998. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/ MVA vaccination regime. Vaccine 16:439-445.
22. Hanke, T., T. J. Blanchard, J. Schneider, G. S. Ogg, R. Tan, M. Becker, S. C. Gilbert, A. V. S. Hill, G. L. Smith, and A. McMichael. 1998. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. J. Gen. Virol. 79:83-90.
23. Hirsch, V., T. R. Fuerst, G. Sutter, M. W. Carroll, L. C. Yang, S. Golstein, M. Piatak, W. R. Elkins, W. G. Alvord, D. Montefiori, B. Moss, and J. D. Lifson. 1996. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70:3741-3752.
24. Holzer, G. W., G. Remp, G. Antoine, M. Pfleiderer, O. M. Enzersberger, W. Emsenhuber, T. Hāmmerle, F. Gruber, C. Urban, F. G. Falkner, and F. Dorner. 1999. Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression. J. Virol. 73:4536-4542.
25. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189:991-998.
26. Kündig, T. M., A. Shahinian, K. Kawai, H.-W. Mittrücker, E. Sebzda, M. F. Bachmann, T. W. Mak, and P. S. Ohashi. 1996. Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity 5:41-52.
27. Kunicka, J. E., M. A. Talle, G. H. Denhart, M. Brown, C. A. Prince, and G. Goldstein. 1993. Immunosuppression by glucocorticoids: inhibition of production of multiple lymphokines by in vivo administration of dexamethasone. Cell. Immunol. 149:39-49.
28. Lau, L. L., B. D. Jamieson, T. Somasundaram, and R. Ahmed. 1994. Cytotoxic T-cell memory without antigen. Nature 369:648-652.
29. Lee, M. S., J. M. Roos, L. C. McGuigan, K. A. Smith, N. Cornier, L. K. Cohen, B. E. Roberts, and L. G. Payne. 1992. Molecular attenuation of vaccinia virus: mutant generation and animal characterization. J. Virol. 66: 2617-2630.
30. Liew, F. Y., and C. R. Parish. 1974. Lack of correlation between cell-mediated immunity to the carrier and the carrier-hapten helper effect. J. Exp. Med. 139:779-784.
31. Mackett, M., G. L. Smith, and B. Moss. 1982. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc. Natl. Acad. Sci. USA 79: 7415-7419.
32. Mayr, A., V. Hoschstein-Mintzel, and H. Stickl. 1975. Abstammung, eigenschaftenund Verwendung des attenuierten Vaccinia-Stammes MVA. Infection 3:6-16.
33. Mayr, A., H. Stickl, H. K. Muller, K. Denner, and H. Singer. 1978. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behaviour in organisms with a debilitated defence mechanism. Zentbl. Backteriol. Hyg. B 167:375-390.
34. Meyer, H., G. Sutter, and A. Mayr. 1991. Mapping of deletions in the genome of highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72:1031-1038.
35. Miyahira, Y., A. García-Sastre, D. Rodriguez, J. R. Rodriguez, K. Murata, M. Tsuji, P. Palese, M. Esteban, F. Zavala, and R. S. Nussenzweig. 1998. Recombinant viruses expressing a human malaria antigen elicit protective immune CD88+ T cell responses in mice. Proc. Natl. Acad. Sci. USA 95:3954-3959.
36. Montoya, M., and M. del Val. 1999. Intracellular rate-limiting steps in MHC class I antigen processing. J. Immunol. 163:1914-1922.
37. Moss, B., M. W. Carroll, L. S. Wyatt, J. R. Bennink, V. Hirsch, S. Golstein, W. R. Elkins, T. R. Fuerst, J. D. Lifson, M. Piatak, N. P. Restifo, W. Overwijk, R. Chamberlain, S. A. Rosenberg, and G. Sutter. 1996. Host range restricted non-replicating vaccinia virus vectors as vaccine candidates. Adv. Exp. Med. Biol. 397:7-13.
38. Murray, J. S. 1998. How the MHC selects Th1/Th2 immunity? Immunol Today 19:157-163.
39. Panicali, D., and E. Paoletti. 1982. Construction of poxvirus as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc. Natl. Acad. Sci. USA 79: 4927-4931.
40. Parish, C. R. 1996. Immune deviation: a historical perspective. Immunol. Cell Biol. 74:449-456.
41. Redfield, R. R., D. C. Wright, W. D. James, T. S. Jones, C. Brown, and D. S. Burke. 1987. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N, Engl. J. Med. 316:673-676.
42. Rodríguez, D., J. R. Rodríguez, J. F. Rodríguez, D. Trauber, and M. Esteban. 1989. Highly attenuated vaccinia virus mutants for the generation of safe recombinants viruses. Proc. Natl. Acad. Sci. USA 86:1287-1291.
43. Rodríguez, J. F., D. Rodríguez, J. R. Rodríguez, E. B. McGowan, and M. Esteban. 1988. Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals. Proc. Natl. Acad. Sci. USA 85:1667-1671.
44. Rodríguez, J. R., C. Risco, J. L. Carrascosa, M. Esteban, and D. Rodríguez. 1997. Characterization of early stages in vaccinia virus membrane biogenesis: implications of the 21-kilodalton protein and a newly identified 15-kilodalton envelope protein. J. Virol. 71:1821-1833.
45. Rowland-Jones, S., R. Tan, and A. J. McMichael. 1997. The role of cellular immunity in protection against HIV infection. Adv. Immunol. 65:277-346.
46. Ruzek, M. C., A. H. Millert, S. M. Opal, B. D. Pearce, and C. A. Biron. 1997. Characterization of early cytokine responses and an interleukin (IL-6)-dependent pathway of endogenous glucocorticoid induction during murine cytomegalovirus infection. J. Exp. Med. 185:1185-1192.
47. Scheleimer, R. P., A. Jacques, H. S. Shin, L. M. Lichstein, and M. Plaut, 1984. Inhibition of T cell-mediated cytotoxicity by anti-inflammatory steroids. J. Immunol. 132:266-271.
48. Schmitz, J. E., M. J. Kuroda, S. Santra, V. G. Sasseville, M. A. Simon, M. A. Lifton, P. Racz, K. Tenner-Racz, M. Dalesandro, B. J. Scallon, J. Ghrayeb, M. A. Forman, D. C. Montefiori, E. P. Rieber, N. L. Letvin, and K. A. Reimann. 1999. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283:857-860.
49. Sedegah, M., T. R. Jones, M. Kaur, R. Hedstrom, P. Hobart, J. A. Tine, and S. L. Hoffman. 1998. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl. Acad. Sci. USA 95:7648-7653.
50. Seth, A., I. Ourmanov, M. J. Kuroda, J. E. Schmitz, M. W. Carroll, L. S. Wyatt, B. Moss, M. A. Forman, V. M. Hirsch, and N. L. Letvin. 1998. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer. Proc. Natl. Acad. Sci. USA 95:10112-10116.
51. Shida, H., Y. Hinuma, M. Hatanaka, M. Morita, M. Kidokoro, K. Suzuki, T. Maruyama, F. Takahashi-Nishimaki, M. Sugimoto, R. Kitamura, T. Miyazawa, and M. Hayami. 1988. Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene. J. Virol. 62:4474-4480.
52. Smith, G. L., J. A. Symons, A. Khanna, A. Vanderplasschen, and A. Alcamí. 1997. Vaccinia virus immune evasion. Immunol. Rev. 159:137-154.
53. Sutter, G., and B. Moss. 1992. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89:10847-10851.
54. Sutter, G., L. S. Wyatt, P. L. Foley, J. R. Bennink, and B. Moss. 1994. A recombinant vector derived from the host-range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12:1032-1040.
55. Taylor, J., R. Weinberg, J. Tartaglia, C. Richardson, G. Alkhatib, D. Breidis, M. Appel, E. Norton, and E. Paoletti. 1992. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology 187:321-328.
56. Werner, G. T., U. Jentsch, E. Metzger, and J. Simon. 1980. Studies on poxvirus infection in irradiated animals. Arch, Virol. 64:247-256.
57. World Health Organization. 1980. The global eradication of smallpox. Final report of the global commission for the certification of smallpox eradication. History of international public health, no. 4. World Health Organization, Geneva, Switzerland.
58. Wyatt, L., B. Moss, and S. Rozenblatt. 1995. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology 210:202-205.
59. Wyatt, L., S. T. Shors, B. R. Murphy, and B. Moss. 1996. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14:1451-1458.